Feb 2020 - Global Life Science Business Partnering - News & Updates

Highlights of February 2020

  1. Cipla Medpro, wholly owned subsidiary of Cipla Limited, India (“Cipla”) and South Africa’s third largest pharmaceutical company in the private sector, has recently concluded an exclusive agreement securing originator and authorized generic brands of an atypical anti-psychotic drug, Quetiapine. 
  2. Strides Pharma Science inks deal with Pharmaceutics to buy 18 ANDAs for US.
  3. Curis, Aurigene announce amendment of collaboration.
  4. China’s Sihuan collaborates with Hetero Drugs.
  5. Wockhardt selling plant and piece of its business to Dr. Reddy's for US$260 Million.
  6. Cipla announces acquisition of 4 nutrition products portfolio from Wanbury.
  7. Glenmark Inks Licensing Pact With Hikma For Commercialization Of Nasal Spray Ryaltris In U.S.
  8. Mumbai based veterinary API major, Lasa Supergenerics announced its acquisition Harishree Aromatics which is in the manufacturing of Veterinary API & Other Pharmaceuticals Intermediates.
  9. Spine-focused Alphatec moves to buy EOS imaging for US$122 Million.
  10. Genentech pays Bicycle Therapeutics US$30 Million upfront to form discovery-stage immuno-oncology pact.
  11. Eisai acquires Chinese rights to hyperuricemia and gout drug from Fuji Yakuhin.
  12. AstraZeneca divests global rights to Movantik to RedHill Biopharma.

Updates at Aagami

  • Existing client, a Menlo Park, California based Innovative Biotech, gave an extended assignment to Aagami for finding a buyer for their IP Portfolio consisting of more than 40 PEGylation related patents.
  • Aagami CEO Dinesh Jain to travel to India with Australian client to finalize a deal, with a large pharma company.
  • Aagami to attend BIO International Convention 2020.

Some of the partnering opportunities available at Aagami are: 

  1. Available for Licensing: DriDose® - a Platform Technology for the delivery of a dry powder drug formulation into the nasal cavity.
  2. Available for IP Acquisition: Next-Generation PEGylation(PharmaPEG®) technology & associated assets.
  3. Seeking Investment / Partnering: Drug to treat alcohol poisoning(Breakthrough, life-saving); Another Drug to prevent hangover and Asian Flush; quick to market solution which works safely and efficiently. It could also slow down Parkinson’s.
  4. Seeking Investment & Partnering: Algae Technology - for Beta Carotene, Lutein, DHA and others (Innovative Process and Cost Optimized).
  5. Available for Licensing: Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
  6. Available for Licensing: Diabetic drug for the treatment of severe hypoglycaemic reactions using Dridose® nasal dry powder formulation; successfully completed a proof of concept clinical trial.
×
Twitter